Glaukos closes Avedro acquisition to expand corneal health franchise
Glaukos acquisition of Avedro : Glaukos Corporation, a California-based ophthalmic medical technology and pharmaceutical company, has completed its previously announced acquisition of Avedro. Based in ... Read More
Constellation Brands, E. & J. Gallo Winery sign revised deal to address FTC concerns
US drinks companies Constellation Brands and E. & J. Gallo Winery have agreed to revise their previously announced $1.7 billion deal in order to address ... Read More
AbbVie, Scripps Research to collaborate on developing new therapeutics
US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for ... Read More
Astellas Pharma to acquire US gene therapy company Audentes Therapeutics
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about ... Read More
Global Blood Therapeutics bags Oxbryta FDA approval for sickle cell disease
Oxbryta FDA approval : Global Blood Therapeutics (GBT), a California-based biopharma company, has bagged approval for Oxbryta (voxelotor) tablets from the US Food and Drug ... Read More
Charles Schwab, TD Ameritrade sign $26bn merger deal
Charles Schwab acquisition of TD Ameritrade: Charles Schwab, a California-based bank and stock brokerage firm, has signed an all-stock deal valued at around $26 billion ... Read More
Mynosys Cellular Devices raises $25m from Decheng Capital
Mynosys Cellular Devices, which manufactures the Zepto cataract surgery device, has secured $25 million in a funding round led by investment firm Decheng Capital. The ... Read More
Viking Therapeutics initiates VOYAGE study for VK2809 in NASH
Viking Therapeutics has initiated the VOYAGE study, a phase 2b clinical trial of its liver-selective thyroid hormone receptor beta agonist VK2809 in patients with biopsy-confirmed ... Read More
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquisition of Calporta : Merck has acquired Calporta Therapeutics from COI Pharmaceuticals in a deal worth up to $576 million, as per the latest ... Read More
Cancer immunotherapy company EpicentRx raises $35m in Series D round
EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of ... Read More